# Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

> **NCT03071692** · PHASE3 · TERMINATED · sponsor: **Kowa Research Institute, Inc.** · enrollment: 10544 (actual)

## Conditions studied

- Type2 Diabetes
- Dyslipidemia

## Interventions

- **DRUG:** K-877
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03071692
- **Lead sponsor:** Kowa Research Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-23
- **Primary completion:** 2022-07-27
- **Final completion:** 2022-07-27
- **Target enrollment:** 10544 (ACTUAL)
- **Why stopped:** The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03071692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03071692, "Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03071692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*